CytomX Historical Income Statement
CTMX Stock | USD 4.50 0.63 12.28% |
Historical analysis of CytomX Therapeutics income statement accounts such as Interest Expense of 2.1 M, Selling General Administrative of 28.8 M or Total Revenue of 54.2 M can show how well CytomX Therapeutics performed in making a profits. Evaluating CytomX Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of CytomX Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining CytomX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CytomX Therapeutics is a good buy for the upcoming year.
CytomX |
About CytomX Income Statement Analysis
CytomX Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to CytomX Therapeutics shareholders. The income statement also shows CytomX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
CytomX Therapeutics Income Statement Chart
CytomX Therapeutics Income Statement is one of the three primary financial statements used for reporting CytomX's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of CytomX Therapeutics revenue and expense. CytomX Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, CytomX Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 86.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2 M in 2024. Add Fundamental
Total Revenue
Total revenue comprises all receipts CytomX Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of CytomX Therapeutics minus its cost of goods sold. It is profit before CytomX Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of CytomX Therapeutics. It is also known as CytomX Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from CytomX Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of CytomX Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most accounts from CytomX Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.At this time, CytomX Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 86.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 69.6M | 53.2M | 99.0M | 53.9M | Total Revenue | 69.6M | 53.2M | 101.2M | 54.2M |
CytomX Therapeutics income statement Correlations
Click cells to compare fundamentals
CytomX Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CytomX Therapeutics income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 2.6M | 2.6M | 2.7M | 2.4M | 2.2M | 2.0M | |
Interest Expense | 10.8M | 1.8M | 172K | 2.0M | 2.3M | 2.1M | |
Selling General Administrative | 36.8M | 36.0M | 39.2M | 42.8M | 30.0M | 28.8M | |
Total Revenue | 57.5M | 100.4M | 69.6M | 53.2M | 101.2M | 54.2M | |
Gross Profit | 57.5M | 100.4M | 69.6M | 53.2M | 99.0M | 53.9M | |
Other Operating Expenses | 168.4M | 149.0M | 153.4M | 154.5M | 107.7M | 115.4M | |
Operating Income | (110.9M) | (48.6M) | (83.8M) | (101.3M) | (6.5M) | (6.8M) | |
Ebit | (110.9M) | (48.6M) | (83.8M) | (101.3M) | (6.5M) | (6.8M) | |
Research Development | 131.6M | 112.9M | 114.2M | 111.6M | 75.7M | 86.4M | |
Ebitda | (108.3M) | (46.0M) | (81.1M) | (98.9M) | (4.3M) | (4.5M) | |
Cost Of Revenue | 105.5M | 0.0 | 5.8M | 5.9M | 2.2M | 2.1M | |
Total Operating Expenses | 168.4M | 149.0M | 153.4M | 154.5M | 105.5M | 115.2M | |
Income Before Tax | (102.7M) | (46.8M) | (83.6M) | (99.3M) | 3.3M | 3.5M | |
Total Other Income Expense Net | 8.2M | 1.8M | 172K | 2.0M | 9.8M | 10.3M | |
Net Income | (102.2M) | (32.9M) | (80.6M) | (97.3M) | (569K) | (597.5K) | |
Income Tax Expense | (427K) | (13.9M) | (3.0M) | (2.0M) | 3.9M | 4.1M | |
Net Income From Continuing Ops | (102.2M) | (32.9M) | (83.6M) | (115.9M) | (10.2M) | (10.7M) | |
Net Income Applicable To Common Shares | (102.2M) | (32.9M) | (83.6M) | (115.9M) | (104.3M) | (109.5M) | |
Tax Provision | 14.3M | (427K) | (13.9M) | 0.0 | 2.8M | 3.0M | |
Interest Income | 8.4M | 1.8M | 255K | 1.7M | 8.1M | 4.1M | |
Net Interest Income | 8.4M | 1.8M | 255K | 1.7M | 8.1M | 4.3M | |
Non Operating Income Net Other | 7.6M | 8.2M | 1.8M | 172K | 154.8K | 147.1K | |
Reconciled Depreciation | 2.6M | 2.6M | 2.7M | 2.4M | 2.3M | 2.5M |
Pair Trading with CytomX Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with CytomX Stock
0.81 | VKTX | Viking Therapeutics | PairCorr |
Moving against CytomX Stock
0.57 | OVID | Ovid Therapeutics Financial Report 3rd of May 2024 | PairCorr |
The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.
The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Transaction History View history of all your transactions and understand their impact on performance | |
Stocks Directory Find actively traded stocks across global markets |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.322 | Return On Assets (0.02) | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.